APO Research
Talk to an analyst

APO RESEARCH · REPORT

Rivaroxaban

Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.

Selected research

Market Structure

Global Rivaroxaban Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

1 January 2026177 pages

Choose your research edition.

Industry ResearchRivaroxaban Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Rivaroxaban Industry Growth and Trends Forecast to 203270 pages · $3,450 USDMarket StructureGlobal Rivaroxaban Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rivaroxaban Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Rivaroxaban Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.

The major players in global Prom Dresses market include Bayer, Johnson and Johnson, etc. The top 2 players occupy nearly 100% of the market. Europe is the main market, and occupies nearly 100% of the global market. 10 mg is the main type, with a share over 30%. Venous Thromboembolism (VTE) is the main application, which holds a share about 85%.

This report provides an overview of the global Rivaroxaban market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Rivaroxaban and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Rivaroxaban sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Rivaroxaban market size, projected growth trends, production technologies, key applications, and end-use industries.

Rivaroxaban Segment by Company

Bayer

J&J

Rivaroxaban Segment by Type

2.5 mg

10 mg

15 mg

20 mg

Rivaroxaban Segment by Application

Acute Coronary Syndrome (ACS)

Venous Thromboembolism (VTE)

Rivaroxaban Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rivaroxaban market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rivaroxaban and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rivaroxaban.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Rivaroxaban market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Rivaroxaban manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Rivaroxaban in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Rivaroxaban in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Rivaroxaban Industry Trends Table 2. Rivaroxaban Industry Drivers Table 3. Rivaroxaban Industry Opportunities and Challenges Table 4. Rivaroxaban Industry Restraints Table 5. Global Rivaroxaban Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Rivaroxaban Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Rivaroxaban Sales by Manufacturers (M Units) & (2021-2026) Table 8. Global Rivaroxaban Sales Market Share by Manufacturers Table 9. Global Rivaroxaban Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Rivaroxaban Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Rivaroxaban Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Rivaroxaban Manufacturers, Product Type & Application Table 13. Global Rivaroxaban Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Rivaroxaban by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 2.5 mg Table 17. Major Manufacturers of 10 mg Table 18. Major Manufacturers of 15 mg Table 19. Major Manufacturers of 20 mg Table 20. Global Rivaroxaban Sales by Type 2021 VS 2025 VS 2032 (M Units) Table 21. Global Rivaroxaban Sales by Type (2021-2026) & (M Units) Table 22. Global Rivaroxaban Sales by Type (2027-2032) & (M Units) Table 23. Global Rivaroxaban Sales Market Share by Type (2021-2026) Table 24. Global Rivaroxaban Sales Market Share by Type (2027-2032) Table 25. Global Rivaroxaban Revenue by Type 2021 VS 2025 VS 2032 (M Units) Table 26. Global Rivaroxaban Revenue by Type (2021-2026) & (M Units) Table 27. Global Rivaroxaban Revenue by Type (2027-2032) & (M Units) Table 28. Global Rivaroxaban Revenue Market Share by Type (2021-2026) Table 29. Global Rivaroxaban Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Acute Coronary Syndrome (ACS) Table 31. Major Manufacturers of Venous Thromboembolism (VTE) Table 32. Global Rivaroxaban Sales by Application 2021 VS 2025 VS 2032 (M Units) Table 33. Global Rivaroxaban Sales by Application (2021-2026) & (M Units) Table 34. Global Rivaroxaban Sales by Application (2027-2032) & (M Units) Table 35. Global Rivaroxaban Sales Market Share by Application (2021-2026) Table 36. Global Rivaroxaban Sales Market Share by Application (2027-2032) Table 37. Global Rivaroxaban Revenue by Application 2021 VS 2025 VS 2032 (M Units) Table 38. Global Rivaroxaban Revenue by Application (2021-2026) & (M Units) Table 39. Global Rivaroxaban Revenue by Application (2027-2032) & (M Units) Table 40. Global Rivaroxaban Revenue Market Share by Application (2021-2026) Table 41. Global Rivaroxaban Revenue Market Share by Application (2027-2032) Table 42. Global Rivaroxaban Sales by Region: 2021 VS 2025 VS 2032 (M Units) Table 43. Global Rivaroxaban Sales by Region (2021-2026) & (M Units) Table 44. Global Rivaroxaban Sales Market Share by Region (2021-2026) Table 45. Global Rivaroxaban Sales Forecasted by Region (2027-2032) & (M Units) Table 46. Global Rivaroxaban Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Rivaroxaban Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 48. North America Rivaroxaban Sales by Country (2021-2026) & (M Units) Table 49. North America Rivaroxaban Sales by Country (2027-2032) & (M Units) Table 50. Europe Rivaroxaban Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 51. Europe Rivaroxaban Sales by Country (2021-2026) & (M Units) Table 52. Europe Rivaroxaban Sales by Country (2027-2032) & (M Units) Table 53. Asia Pacific Rivaroxaban Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 54. Asia Pacific Rivaroxaban Sales by Country (2021-2026) & (M Units) Table 55. Asia Pacific Rivaroxaban Sales by Country (2027-2032) & (M Units) Table 56. South America, Middle East and Africa Rivaroxaban Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 57. South America, Middle East and Africa Rivaroxaban Sales by Country (2021-2026) & (M Units) Table 58. South America, Middle East and Africa Rivaroxaban Sales by Country (2027-2032) & (M Units) Table 59. Global Rivaroxaban Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Rivaroxaban Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Rivaroxaban Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Rivaroxaban Revenue Market Share by Region (2021-2026) Table 63. Global Rivaroxaban Revenue Market Share by Region (2027-2032) Table 64. Bayer Company Information Table 65. Bayer Business Overview Table 66. Bayer Rivaroxaban Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Bayer Rivaroxaban Product Portfolio Table 68. Bayer Recent Development Table 69. J&J Company Information Table 70. J&J Business Overview Table 71. J&J Rivaroxaban Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. J&J Rivaroxaban Product Portfolio Table 73. J&J Recent Development Table 74. Key Raw Materials Table 75. Raw Materials Key Suppliers Table 76. Rivaroxaban Distributors List Table 77. Rivaroxaban Customers List Table 78. Research Programs/Design for This Report Table 79. Authors List of This Report Table 80. Secondary Sources Table 81. Primary Sources List of Figures Figure 1. Rivaroxaban Product Image Figure 2. Global Rivaroxaban Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rivaroxaban Market Size (2021-2032) & (US$ Million) Figure 4. Global Rivaroxaban Sales (2021-2032) & (M Units) Figure 5. Global Rivaroxaban Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Rivaroxaban Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 2.5 mg Image Figure 9. 10 mg Image Figure 10. 15 mg Image Figure 11. 20 mg Image Figure 12. Global Rivaroxaban Sales by Type (2021 VS 2025 VS 2032) & (M Units) Figure 13. Global Rivaroxaban Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Rivaroxaban Sales Market Share by Type (2021-2032) Figure 15. Global Rivaroxaban Revenue by Type (2021 VS 2025 VS 2032) & (M Units) Figure 16. Global Rivaroxaban Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Rivaroxaban Revenue Market Share by Type (2021-2032) Figure 18. Acute Coronary Syndrome (ACS) Image Figure 19. Venous Thromboembolism (VTE) Image Figure 20. Global Rivaroxaban Sales by Application (2021 VS 2025 VS 2032) & (M Units) Figure 21. Global Rivaroxaban Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Rivaroxaban Sales Market Share by Application (2021-2032) Figure 23. Global Rivaroxaban Revenue by Application (2021 VS 2025 VS 2032) & (M Units) Figure 24. Global Rivaroxaban Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Rivaroxaban Revenue Market Share by Application (2021-2032) Figure 26. North America Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 27. North America Rivaroxaban Sales Market Share by Country (2021-2032) Figure 28. U.S. Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 29. Canada Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 30. Mexico Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 31. Europe Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 32. Europe Rivaroxaban Sales Market Share by Country (2021-2032) Figure 33. Germany Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 34. France Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 35. U.K. Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 36. Italy Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 37. Netherlands Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 38. Asia Pacific Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 39. Asia Pacific Rivaroxaban Sales Market Share by Country (2021-2032) Figure 40. China Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 41. Japan Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 42. South Korea Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 43. Southeast Asia Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 44. India Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 45. Australia Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 46. South America, Middle East and Africa Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 47. South America, Middle East and Africa Rivaroxaban Sales Market Share by Country (2021-2032) Figure 48. Brazil Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 49. South Africa Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 50. Saudi Arabia Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 51. Turkey Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 52. Argentina Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 53. UAE Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 54. Egypt Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 55. Chile Rivaroxaban Sales and Growth Rate (2021-2032) & (M Units) Figure 56. Global Rivaroxaban Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Rivaroxaban Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Rivaroxaban Revenue (2021-2032) & (US$ Million) Figure 59. North America Rivaroxaban Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Rivaroxaban Revenue (2021-2032) & (US$ Million) Figure 61. Europe Rivaroxaban Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Rivaroxaban Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Rivaroxaban Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Rivaroxaban Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Rivaroxaban Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Rivaroxaban Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Rivaroxaban Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • 2.5 mg
  • 10 mg
  • 15 mg
  • 20 mg
Applications
  • Acute Coronary Syndrome (ACS)
  • Venous Thromboembolism (VTE)
Companies covered
  • Bayer
  • J&J

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Rivaroxaban Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Rivaroxaban Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Rivaroxaban Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Rivaroxaban Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Rivaroxaban Market Dynamics
  1. 2.1 Rivaroxaban Industry Trends
  2. 2.2 Rivaroxaban Industry Drivers
  3. 2.3 Rivaroxaban Industry Opportunities and Challenges
  4. 2.4 Rivaroxaban Industry Restraints
3 Rivaroxaban Market by Manufacturers
  1. 3.1 Global Rivaroxaban Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Rivaroxaban Sales by Manufacturers (2021-2026)
  3. 3.3 Global Rivaroxaban Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Rivaroxaban Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Rivaroxaban Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Rivaroxaban Manufacturers, Product Type & Application
  7. 3.7 Global Rivaroxaban Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Rivaroxaban Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Rivaroxaban Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Rivaroxaban Tier 1, Tier 2, and Tier 3
4 Rivaroxaban Market by Type
  1. 4.1 Rivaroxaban Type Introduction
  2. 4.1.1 2.5 mg
  3. 4.1.2 10 mg
  4. 4.1.3 15 mg
  5. 4.1.4 20 mg
  6. 4.2 Global Rivaroxaban Sales by Type
  7. 4.2.1 Global Rivaroxaban Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Rivaroxaban Sales by Type (2021-2032)
  9. 4.2.3 Global Rivaroxaban Sales Market Share by Type (2021-2032)
  10. 4.3 Global Rivaroxaban Revenue by Type
  11. 4.3.1 Global Rivaroxaban Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Rivaroxaban Revenue by Type (2021-2032)
  13. 4.3.3 Global Rivaroxaban Revenue Market Share by Type (2021-2032)
5 Rivaroxaban Market by Application
  1. 5.1 Rivaroxaban Application Introduction
  2. 5.1.1 Acute Coronary Syndrome (ACS)
  3. 5.1.2 Venous Thromboembolism (VTE)
  4. 5.2 Global Rivaroxaban Sales by Application
  5. 5.2.1 Global Rivaroxaban Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Rivaroxaban Sales by Application (2021-2032)
  7. 5.2.3 Global Rivaroxaban Sales Market Share by Application (2021-2032)
  8. 5.3 Global Rivaroxaban Revenue by Application
  9. 5.3.1 Global Rivaroxaban Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Rivaroxaban Revenue by Application (2021-2032)
  11. 5.3.3 Global Rivaroxaban Revenue Market Share by Application (2021-2032)
6 Global Rivaroxaban Sales by Region
  1. 6.1 Global Rivaroxaban Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Rivaroxaban Sales by Region (2021-2032)
  3. 6.2.1 Global Rivaroxaban Sales by Region (2021-2026)
  4. 6.2.2 Global Rivaroxaban Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Rivaroxaban Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Rivaroxaban Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Rivaroxaban Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Rivaroxaban Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Rivaroxaban Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Rivaroxaban Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Rivaroxaban Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Rivaroxaban Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Rivaroxaban Revenue by Region
  1. 7.1 Global Rivaroxaban Revenue by Region
  2. 7.1.1 Global Rivaroxaban Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Rivaroxaban Revenue by Region (2021-2026)
  4. 7.1.3 Global Rivaroxaban Revenue by Region (2027-2032)
  5. 7.1.4 Global Rivaroxaban Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Rivaroxaban Revenue (2021-2032)
  8. 7.2.2 North America Rivaroxaban Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Rivaroxaban Revenue (2021-2032)
  11. 7.3.2 Europe Rivaroxaban Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Rivaroxaban Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Rivaroxaban Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Rivaroxaban Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Rivaroxaban Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Bayer
  2. 8.1.1 Bayer Company Information
  3. 8.1.2 Bayer Business Overview
  4. 8.1.3 Bayer Rivaroxaban Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bayer Rivaroxaban Product Portfolio
  6. 8.1.5 Bayer Recent Developments
  7. 8.2 J&J
  8. 8.2.1 J&J Company Information
  9. 8.2.2 J&J Business Overview
  10. 8.2.3 J&J Rivaroxaban Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 J&J Rivaroxaban Product Portfolio
  12. 8.2.5 J&J Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Rivaroxaban Value Chain Analysis
  2. 9.1.1 Rivaroxaban Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Rivaroxaban Production Mode & Process
  6. 9.2 Rivaroxaban Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Rivaroxaban Distributors
  9. 9.2.3 Rivaroxaban Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst